Chemical Genetics of Plasmodium Kinases

疟原虫激酶的化学​​遗传学

• 批准号: 7879102
• 负责人: DEBOPAM CHAKRABARTI
• 金额: $ 0.7万
• 依托单位: UNIVERSITY OF CENTRAL FLORIDA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-14 至 2010-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7879102
• 关键词: Address; Affect; Alleles; Area; Binding; Binding Sites; CDC2 Protein Kinase; Catalytic Domain; Cell Cycle; Cell Cycle Regulation; Cell Extracts; Cells; Characteristics; Cyclin-Dependent Kinases; Cytokinesis; DNA; DNA biosynthesis; Data; Development; Disease; Drug Delivery Systems; Drug Design; Drug resistance; Electrostatics; Engineering; Environment; Enzymes; Erythrocytes; Eukaryota; Eukaryotic Cell; Exhibits; Family; Gene Expression; Gene Expression Microarray Analysis; Gene Targeting; Generations; Global Change; Goals; Growth; Haploidy; Health; Homologous Gene; Hot Spot; Hydrogen Bonding; Knock-out; Knowledge; Label; Life Cycle Stages; Malaria; Microarray Analysis; Microscopic; Mission; Molecular; Outcome; Parasites; Pathway interactions; Pharmaceutical Preparations; Phenotype; Phosphotransferases; Physiological; Plasmodium; Plasmodium falciparum; Preparation; Prevalence; Property; Proteins; Public Health; Research; Research Personnel; Role; Route; Screening procedure; Shapes; Signal Pathway; Signal Transduction; Site; Solutions; Specificity; Substrate Interaction; Techniques; Therapeutic; Two-Dimensional Gel Electrophoresis; Work; analog; asexual; base; cell growth; cellular targeting; chemical genetics; combat; drug development; experience; human disease; in vivo; inhibitor/antagonist; innovation; killings; loss of function; mutant; novel; novel strategies; novel therapeutics; protein protein interaction; public health relevance; resistant strain; therapeutic target

DESCRIPTION (provided by applicant): Malaria continues to be a global health problem killing 1-2 million people each year. Because of prevalence drug resistance it is urgent to identify new therapeutics for treatment. However, the development of new drugs by traditional screening approaches has lagged behind the required number of molecular entities to combat the disease and the serious problem of drug resistance. Additionally, there are only a few validated drug targets. This underscores the need for novel approaches to identify targets for drug development. Similar to all eukaryotes, cyclin-dependent kinases (CDKs) are likely to be key regulators of the novel intraerythrocytic cell cycle of the malaria parasite, where DNA replicates more than once per cell cycle without cytokinesis. Although several homologues of CDK-like kinases have been identified in P. falciparum, there is a fundamental gap in understanding about their physiological function. The long-term goal is to develop novel malaria therapeutics targeting Plasmodium CDK-like kinases. The objective of this application is to elucidate PfPK5, an essential closest Plasmodium homologue of metazoan CDK1, substrates through loss-of-function studies using chemical genetic approach. The chemical genetic approach will specifically label substrates of a given kinase using ATP analogs. The rationale for these proposed studies is that once PfPK5 physiological substrates are identified, it is expected that PfPK5- specific sites of protein-protein interactions will be exploited to develop mechanism-based route of interfering with PfPK5 function or the pathway where PfPK5 belongs. Thus, the proposed research is relevant to NIH's mission that pertains to developing fundamental knowledge that will potentially help to reduce the burden of human disease. Guided by strong preliminary data two specific aims will be pursued: (1) Identify P. falciparum proteins that are directly phosphorylated by PfPK5 by generating mutant kinases that are specifically able to utilize ATP analogs compared to the wild type kinases. Phosphorylated proteins will be identified by two-dimensional gel electrophoresis followed by mass spectrometric analysis. Candidate PfPK5 substrates will be validated. (2) Analyze phenotypic changes following loss of PfPK5 function by selective in vivo inhibition with ATP analogs. Global changes in gene expression will be analyzed by microarray analysis and phenotypic changes by microscopic and flow cytometric analysis following specific inhibition in PfPK5 activity. The proposed research is significant, because it will fundamentally advance our understanding of the molecular mechanisms of PfPK5 function in regulating Plasmodium falciparum intraerythrocytic life cycle. PUBLIC HEALTH RELEVANCE The proposed studies are of an important and under-investigated area of cell cycle regulation and signaling in Plasmodium falciparum. The proposed research has relevance to public health, because it will increase our understanding of the function of CDK-like kinases in Plasmodium falciparum that will aid in identifying parasite-specific signaling pathways and novel drug targets.

描述（由申请人提供）：疟疾仍然是一个全球健康问题，每年造成100万至200万人死亡。由于耐药的普遍存在，迫切需要寻找新的治疗方法。然而，通过传统的筛选方法开发新药已经落后于对抗疾病和严重的耐药性问题所需的分子实体数量。此外，只有少数经过验证的药物靶点。这强调需要新的方法来确定药物开发的靶点。与所有真核生物相似，细胞周期蛋白依赖性激酶（CDKs）可能是疟原虫新型红细胞内细胞周期的关键调节因子，其中DNA在没有细胞分裂的情况下每个细胞周期复制不止一次。虽然已经在恶性疟原虫中发现了一些cdk样激酶的同源物，但对其生理功能的理解仍存在根本性的空白。长期目标是开发针对疟原虫cdk样激酶的新型疟疾疗法。本应用程序的目的是阐明PfPK5，一个重要的近亲疟原虫的后生动物CDK1，底物通过功能丧失研究使用化学遗传学方法。化学遗传方法将使用ATP类似物特异性标记给定激酶的底物。这些研究的基本原理是，一旦确定了PfPK5生理底物，预计将利用PfPK5蛋白-蛋白相互作用的特异性位点来开发基于机制的干扰PfPK5功能的途径或PfPK5所在的途径。因此，拟议的研究与NIH的使命有关，即发展有助于减轻人类疾病负担的基础知识。在强有力的初步数据的指导下，将实现两个特定目标：(1)通过产生与野生型激酶相比能够特异性利用ATP类似物的突变激酶，确定被PfPK5直接磷酸化的恶性疟原虫蛋白。磷酸化蛋白将通过二维凝胶电泳和质谱分析鉴定。候选PfPK5底物将被验证。(2)通过ATP类似物在体内选择性抑制PfPK5功能丧失后的表型变化。基因表达的整体变化将通过微阵列分析和表型变化通过显微镜和流式细胞术分析在PfPK5活性特异性抑制后。本研究具有重要意义，因为它将从根本上推进我们对PfPK5调控恶性疟原虫红细胞内生命周期的分子机制的理解。拟议的研究是恶性疟原虫细胞周期调控和信号传导的一个重要且未被充分研究的领域。这项拟议的研究与公共卫生相关，因为它将增加我们对恶性疟原虫cdk样激酶功能的理解，这将有助于确定寄生虫特异性信号通路和新的药物靶点。